Northern Trust Corp Has $11.34 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS

Northern Trust Corp trimmed its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 5.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 518,694 shares of the company’s stock after selling 28,582 shares during the quarter. Northern Trust Corp owned about 0.41% of Apellis Pharmaceuticals worth $11,344,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in APLS. Assetmark Inc. raised its stake in Apellis Pharmaceuticals by 3,938.7% during the 1st quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock worth $27,000 after buying an additional 1,221 shares during the period. GF Fund Management CO. LTD. increased its position in shares of Apellis Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock valued at $70,000 after acquiring an additional 573 shares during the last quarter. Legacy Capital Group California Inc. increased its position in shares of Apellis Pharmaceuticals by 32.8% during the first quarter. Legacy Capital Group California Inc. now owns 9,554 shares of the company’s stock valued at $209,000 after acquiring an additional 2,359 shares during the last quarter. Nomura Holdings Inc. bought a new position in Apellis Pharmaceuticals during the fourth quarter valued at $223,000. Finally, GAMMA Investing LLC grew its holdings in Apellis Pharmaceuticals by 1,795.4% during the first quarter. GAMMA Investing LLC now owns 10,235 shares of the company’s stock valued at $224,000 after purchasing an additional 9,695 shares during the period. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Trading Up 3.1%

Shares of Apellis Pharmaceuticals stock opened at $28.65 on Friday. The company has a fifty day moving average of $22.75 and a 200 day moving average of $21.39. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $41.94. The company has a market capitalization of $3.62 billion, a P/E ratio of -15.74 and a beta of 0.73. The company has a debt-to-equity ratio of 2.90, a quick ratio of 3.16 and a current ratio of 3.77.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Thursday, July 31st. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.11. Apellis Pharmaceuticals had a negative net margin of 30.24% and a negative return on equity of 116.09%. The business had revenue of $171.39 million during the quarter, compared to the consensus estimate of $187.91 million. During the same quarter in the prior year, the firm earned ($0.30) EPS. The business’s revenue was down 10.6% on a year-over-year basis. On average, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In related news, General Counsel David O. Watson sold 5,000 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $27.80, for a total value of $139,000.00. Following the completion of the transaction, the general counsel owned 123,730 shares of the company’s stock, valued at approximately $3,439,694. This trade represents a 3.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Cedric Francois sold 175,037 shares of the stock in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $28.19, for a total transaction of $4,934,293.03. Following the completion of the transaction, the chief executive officer directly owned 357,909 shares of the company’s stock, valued at approximately $10,089,454.71. The trade was a 32.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 399,638 shares of company stock valued at $9,910,962 in the last three months. Insiders own 6.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Raymond James Financial dropped their price objective on Apellis Pharmaceuticals from $52.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, August 1st. Bank of America raised their price target on Apellis Pharmaceuticals from $23.00 to $24.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Cantor Fitzgerald lifted their price objective on Apellis Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Wells Fargo & Company lifted their price objective on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the stock an “equal weight” rating in a report on Monday, June 2nd. Finally, Scotiabank reduced their price target on Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating on the stock in a report on Thursday, May 8th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.12.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).